Pharmacokinetics and Metabolism of [14C] BMS-986231 in Healthy Male Participants

• Status: Completed
• Trial end date: 2017-07-20
• Target enrollment: 0
• Participant gender: Male

Summary

An intravenous infusion in healthy subjects to obtain information about the absorption, metabolism, and excretion (AME) of BMS-986231

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bristol-Myers Squibb

Criteria

Inclusion Criteria:

• Signed Informed Consent

• Target population: Healthy males with no clinically significant deviations from normal in medical history, physical examinations, vital signs, electrocardiograms (ECGs), physical measurements, and clinical laboratory tests

• Body weight between 75 and 95 kg, inclusive; body mass index (BMI) between 18 to 32 kg/m2.

Exclusion Criteria:

• History of chronic illness

• Chronic headaches

• Recurrent dizziness

• Personal or family history of heart disease

• Personal history of bleeding diathesis

Other protocol defined inclusion/exclusion criteria could apply